Sanofi (NASDAQ: SNY) and Kymab have entered into a deal that will see Sanofi acquire Kymab for an initial payment of approximately $1.1 billion. Sanofi will make additional payments of up to $350 million in case certain milestones are reached.
The transaction will result in Sanofi having all global rights to the newly developed antibody KY1005, a human monoclonal antibody that works and differently from other antibodies that work at the receptor level. KY1005 binds to the OX40-Ligand, which provides a unique tool to treat a wide range of immune-mediated diseases and inflammatory disorders.
According to Kymab, KY1005 met both primary endpoints in the Phase 2a trial in August 2020, studying moderate to severe patients with atopic dermatitis who experienced an inadequate response to topical corticosteroids. Compared to placebo, KY1005 showed a consistent clinical effect across various key endpoints such as EASI (Eczema Area and Severity Index) and other objective measurements.
Furthermore, Kymab also features the ICOS agonist monoclonal antibody KY1044, which is currently being developed as a monotherapy and combined with an anti-PD-L1. The acquisition will also enable Sanofi to develop new antibody technologies, as well as new research capabilities.
Sanofi (NASDAQ: SNY) rose by 0.75% from its recent closing price to its recent 1-year high price of $55.00. Last five trading sessions, the company’s stock price dropped -0.29%.
Sanofi’s (NASDAQ: SNY) price-to-earnings ratio is 8.86 x from its current earnings ratio. Moreover, the 36-month beta for SNY is 0.54. The different analysts’ opinions of the stock are interesting, with 14 analysts rating the stock as “buy” while only 2 rated it as “overweight” while 7 rated it as “hold.” Analysts price the stock at $61.94, $16.38 above the current price. SNY has a public float of $2.25B, and shorts hold 0.14% of that float. SNY traded 1.54M shares on average today.